LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Abierto

SectorSanidad

91.64 1.07

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

89.52

Máximo

92.2

Métricas clave
By Trading Economics
Ingresos	-8.1M -56M
Ventas	2.9M 60M
BPA	-0.83
Margen de beneficios	-92.559
Empleados	414
EBITDA	-9.7M -52M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+52.27% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	301M 6.2B
Apertura anterior	90.57
Cierre anterior	91.64

Noticias sobre sentimiento de mercado

By Acuity

68%

32%

295 / 344 Clasificación en Healthcare

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 may 2026, 21:33 UTC

Ganancias

Correction to Salesforce 1Q Sales, Profit Rise Article

27 may 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 may 2026, 20:18 UTC

Ganancias

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 may 2026, 23:49 UTC

Charlas de Mercado

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 may 2026, 23:39 UTC

Charlas de Mercado

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 may 2026, 23:34 UTC

Charlas de Mercado

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 may 2026, 23:34 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 may 2026, 23:08 UTC

Charlas de Mercado

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 may 2026, 22:21 UTC

Charlas de Mercado

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 may 2026, 21:29 UTC

Acciones populares

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 may 2026, 21:08 UTC

Ganancias

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 may 2026, 21:02 UTC

Ganancias

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 may 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 may 2026, 20:55 UTC

Ganancias

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 may 2026, 20:48 UTC

Ganancias

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 may 2026, 20:45 UTC

Ganancias

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 may 2026, 20:34 UTC

Adquisiciones, fusiones, absorciones

Webster Financial Stockholders Approve Sale to Banco Santander

27 may 2026, 20:32 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 may 2026, 20:32 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 may 2026, 20:32 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 may 2026, 20:30 UTC

Ganancias

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 may 2026, 20:30 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 may 2026, 20:22 UTC

Ganancias

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 may 2026, 20:16 UTC

Ganancias

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 may 2026, 20:13 UTC

Ganancias

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 may 2026, 20:13 UTC

Ganancias

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 may 2026, 20:13 UTC

Ganancias

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 may 2026, 20:12 UTC

Ganancias

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 may 2026, 20:12 UTC

Ganancias

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

52.27% repunte

Estimación a 12 Meses

Media 136.77 USD 52.27%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

295 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.